Ribavirin approved for hepatitis C combination treatment.
James
J S
JS
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D004338:Drug Combinations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin